Communicating Risks during Pregnancy: A Workshop on the Use of Data from Animal Developmental Toxicity Studies in Pregnancy Labels for Drugs

Birth Defects Research Part A - Clinical and Molecular Teratology

Volumn 70, Issue 1, 2004, Pages 7-12

  Scialli, Anthony R ^a,h   Buelke Sam, Judy L ^b   Chambers, Christina D ^c   Friedman, Jan M ^d   Kimmel, Carole A ^e   Polifka, Janine E ^f   Tassinari, Melissa S ^g  

^a GEORGETOWN UNIVERSITY   (United States)

^b Toxicology Services   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^f UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^g PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^h GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AREA UNDER THE CURVE; BIOTRANSFORMATION; CONFERENCE PAPER; DEVELOPMENTAL DISORDER; DRUG ADMINISTRATION ROUTE; DRUG INFORMATION; DRUG LABELING; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDICAL SOCIETY; NONHUMAN; PRACTICE GUIDELINE; PREGNANCY; PRESCRIPTION; PRIORITY JOURNAL; REPRODUCTIVE TOXICITY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TERATOLOGY;

ANIMALS; FEMALE; FETAL DISEASES; HUMANS; MODELS, ANIMAL; PREGNANCY; PREGNANCY COMPLICATIONS; TOXICOLOGY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

ANIMALIA;

EID: 1042278062     PISSN: 15420752     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdra.10150     Document Type: Conference Paper

References (19)

1. Addis A, Sharabi S, Bonati M. 2000. Risk classification systems for drug use during pregnancy. Are they a reliable source of information? Drug Saf 23:245-253.
2. Addis A, Magrini N, Mastroiacovo P. 2001. Drug use during pregnancy. Lancet 35(9258):800.
3. Alvan G, Danielsson BR, Kihlstrom I, et al. 1995. Classification of drugs for teratogenic risk. Eur J Clin Pharmacol 48:177-178.
4. Boothby LA, Doering PL. 2001. FDA labeling system for drugs in pregnancy. Ann Pharmacother 35:1485-1489.
5. Brent RL. 1982. Drugs and pregnancy: are the insert warnings too dire? Contemp Ob Gyn 20:42-49.
6. Brent RL. 1997. Content and format of labeling for human prescription drugs: Pregnancy labeling; Public hearing [Comments]. Public Hearing. Docket No. 97N-0289.
7. Doering PL, Boothby LA, Cheok M. 2002. Review of pregnancy labeling of prescription drugs: is the current system adequate to inform risks? Am J Obstet Gynecol 187:333-339.
8. Federal Register. 1979. Washington, DC: Office of the Federal Register, National Archives and Records Administration.
9. Friedman JM, Little BB, Brent RL, et al. 1990. Potential human teratogenicity of frequently prescribed drugs. Obstet Gynecol 75:594-599.
10. Friedman JM. 1993. Report of the Teratology Public Affairs Committee symposium on FDA classification of drugs. Teratology 48:5-6.
11. Friedman JM. 2002. Draft guidance for reviewers on the integration of study results to assess concerns about human reproductive and developmental toxicities (Docket No. 99N-2079) [Comments]. Available at: http:// www.fda.gov/ohrms/dockets/dailys/02/Mar02/031202/99n-2079_c000007_vol3.pdf.
12. Lo WY, Friedman JM. 2002. Teratogenicity of recently introduced medications in human pregnancy. Obstet Gynecol 100:465-473.
13. Scialli AR. 1992. A clinical guide to reproductive and developmental toxicology. Boca Raton: CRC Press. pp. 231-255.
14. Scialli AR. 2001. Draft guidance for reviewers on the integration of study results to assess concerns about human reproductive and developmental toxicities (Docket No. 99N-2079) [Comments].
15. Teratology Society Public Affairs Committee. 1994. FDA classification of drugs for teratogenic risk. Teratology 49:446-447.
16. Uhl K, Kennedy DL, Kweder SL. 2002. Risk management strategies in the Physicians' Desk Reference product labels for pregnancy category X drugs. Drug Saf 25:885-892.
17. U.S. Food and Drug Administration. 1997. Content and format of labeling for human prescription drugs: pregnancy labeling: public hearing (Docket No. 97N-0289). Fed Regist 62(147):41061-41063.
18. U.S. Food and Drug Administration. 2001a. Concept paper on pregnancy labeling. Summary of comments from a public hearing and model pregnancy labeling based on recommendations. Available at: http:// www.fda.gov/ohrms/dockets/ac/99/transcpt/3516r1.doc.
19. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. 2001b. Reviewer guidance: integration of study results to assess concerns about human reproductive and developmental toxicities. Available at: http://www.fda.gov/cder/guidance/4625dft.pdf.